中欧丙型肝炎病毒的新治疗选择。
New therapeutic options for HCV in Central Europe.
作者信息
Flisiak Robert, Urbánek Petr, Rokusz Laszlo, Oltman Marian, Makara Mihaly, Janicko Martin
机构信息
Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland.
Department of Internal Medicine, 1 Faculty of Medicine Charles University and Central Military Hospital Prague, Prague, Czech Republic.
出版信息
Clin Exp Hepatol. 2016 Mar;2(1):7-11. doi: 10.5114/ceh.2016.58850. Epub 2016 Mar 24.
New therapeutic options became available in 2015 in the European Union. We present the availability of interferon-free regimens with direct acting antivirals (DAA) in four Central European countries - the Czech Republic, Hungary, Poland and Slovakia - which despite similar historical, geographical and economic situations demonstrate different systems for access to anti-HCV (hepatitis C virus) medication. Treatment of patients in the Czech Republic was based in 2015 on an exceptional individual reimbursement procedure, but regular reimbursement procedures are expected in 2016. In Hungary the decision for treatment is balanced against budget limitations and the national Priority Index system reflecting stage of liver disease, activity of the disease and predictive factors. A reimbursed interferon (IFN)-free therapeutic program for all genotypes, without restrictions related to hepatic fibrosis and treatment history, is already available in Poland. In Slovakia patients with advanced fibrosis are currently selected for possible IFN-free therapy in 2016.
2015年欧盟出现了新的治疗选择。我们介绍了在四个中欧国家（捷克共和国、匈牙利、波兰和斯洛伐克）使用直接作用抗病毒药物（DAA）的无干扰素治疗方案的可及性，尽管这四个国家有着相似的历史、地理和经济情况，但在获取抗丙型肝炎病毒（HCV）药物方面却展现出不同的体系。2015年，捷克共和国的患者治疗基于一项特殊的个人报销程序，但预计2016年将采用常规报销程序。在匈牙利，治疗决策要在预算限制与反映肝病阶段、疾病活动度和预测因素的国家优先指数系统之间进行权衡。波兰已经有了针对所有基因型的报销型无干扰素治疗方案，且不受肝纤维化和治疗史的限制。在斯洛伐克，目前正在挑选有严重纤维化的患者，以便在2016年接受可能的无干扰素治疗。
Zotero 插件